Epithalon Side Effects: Where the Preparation Is the Risk

There is no reviewed adverse event table for this compound. It holds no marketing authorisation in any jurisdiction, so no regulator has assembled one, and there are no registered interventional trials, so no trial identifier is cited here.

That leaves two sources. The first is the published research associated with it, largely from Khavinson and colleagues in St Petersburg, covering cell culture, mice and rats, and human observational work from within that programme. The second is preparation: what happens between a label and a syringe in the hands of whoever bought the vial.

The second source is the one that produces most reported problems, and it is the only one this page can quantify.

Vials of this compound are commonly labelled in tens of milligrams, which puts more material behind every graduation than a buyer used to smaller peptides expects. An error of the same shape therefore carries a larger mass.

Work it on a 50 mg vial with an intended fill of 5 mL, which is 50 divided by 5, or 10 mg per mL. On a U-100 syringe, where one unit is 0.01 mL, five units are 0.05 mL and hold 500 mcg. That is the baseline every row below departs from.

Four of those five rows produce a liquid that looks exactly like the correct one. The barrel reads the same number in every row of the middle column, the vial looks the same, and nothing in the procedure announces the discrepancy. The last row is a decimal place, which is the cheapest mistake in the whole of pharmacy to make and the most expensive to make repeatedly.

The defence is not care, it is a record. Write the labelled mass, the volume added, the concentration those two produce, the syringe type, the volume drawn and the mass that follows. Six entries, taken once, at the bench.

An overshoot deserves separate mention, because it produces no dramatic multiple and never corrects itself. Intend 5 mL and add 5.5 mL, and the concentration becomes 50 divided by 5.5, which is 9.09 mg per mL rather than 10. Five units then hold 455 mcg instead of 500. That is a small discrepancy, it is proportional, and it applies to every withdrawal from that vial for as long as the vial lasts. Nothing about the liquid or the barrel reading reveals it, and the only thing that would have caught it is the volume having been measured and written down at the time it was added.

A sealed vial of dry powder and a punctured vial of solution are not the same item, and the arithmetic that describes the first says nothing about the second.

Reconstituted liquid has a limited life. No stability figure for this compound is asserted here, so treat it with an assumed policy of 28 days refrigerated, since the assumption is what matters. Under that policy, a 50 mg vial reconstituted with 5 mL and drawn 1 mg at a time holds 50 withdrawals, which at one a day is 50 days. The container outlives its own contents by three weeks, and the arithmetic that counted the withdrawals gave no warning, because withdrawal counting has no clock in it.

Repeated puncture is the other change. Each entry through the septum is an opportunity for contamination, and the preservative in bacteriostatic water is doing that work for the whole period. A vial entered once behaves differently from one entered fifty times, and neither the label nor any calculation on this page distinguishes them.

Degradation belongs in the same paragraph, with the same honesty. A concentration is computed once and then quoted for as long as the vial is in use, as though the number were still true. Whether it remains true is a stability question, and this page has no figure for it.

The claim that a compound is well tolerated has a specific meaning: that a population was observed under defined conditions, adverse events were collected systematically, and few were found. None of that has happened here in a form a reader can inspect.

What exists instead is an absence of collection. There is no post marketing surveillance, because there is no marketed product. There is no trial safety database, because there are no registered trials. There is no adverse event reporting route, because there is no approved indication and nobody to report to.

Under those conditions a quiet record is exactly what would be expected whether the compound were harmless or not. Treating that silence as reassurance inverts the logic. The correct statement is that the information does not exist, which is neither good news nor bad news, and it is what should be said instead of the reassuring version.

The research associated with this compound is largely concentrated in one group, and that concentration matters for safety differently from how it matters for benefits.

For a benefit claim, single group work means a finding has been reported but not reproduced. For a safety claim, it means something narrower and more uncomfortable: the conditions under which anyone has looked are the conditions that one programme chose, in the organisms it chose, over the durations it chose. An effect that appears outside those conditions has had no opportunity to be seen.

Independent replication would help with both. Its absence leaves benefit claims unconfirmed and safety claims unexamined, and the second gap gets far less attention than the first because nobody is selling it.

None of this asserts that harm exists. It asserts that the record is not the kind of record from which an absence of harm can be concluded, and that the difference is the entire point.